Stockscreener 앱 받기
2.34
0.00%
0.06
전일 마감가:
$2.28
열려 있는:
$2.38
하루 거래량:
33,520
Relative Volume:
0.03
시가총액:
$4.11M
수익:
$502.40K
순이익/손실:
$-7.91M
주가수익비율:
-0.2347
EPS:
-9.972
순현금흐름:
$-4.32M
1주 성능:
-18.28%
1개월 성능:
+28.81%
6개월 성능:
-49.45%
1년 성능:
-81.90%
1일 변동 폭
$2.2201
$2.38
1주일 범위
$2.21
$2.89
52주 변동 폭
$1.41
$35.99
60 Degrees Pharmaceuticals Inc Stock (SXTP) Company Profile
명칭
60 Degrees Pharmaceuticals Inc
전화
202-327-5422
주소
1025 CONNECTICUT AVENUE NW, WASHINGTON
SXTP을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SXTP
60 Degrees Pharmaceuticals Inc
|
2.35 | 4.11M | 502.40K | -7.91M | -4.32M | -9.972 |
|
VRTX
Vertex Pharmaceuticals Inc
|
501.76 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
606.43 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
658.26 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.69 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
255.06 | 26.89B | 3.81B | -644.79M | -669.77M | -6.24 |
60 Degrees Pharmaceuticals Inc 주식(SXTP)의 최신 뉴스
60 Degrees Pharmaceuticals Announces 2024 Annual Results - ADVFN
60 Degrees Pharmaceuticals (NASDAQ:SXTP) Given “Sell (E+)” Rating at Weiss Ratings - Defense World
60 Degrees Pharmaceuticals, Inc. Announces 1:5 Reverse Stock Split - ADVFN
60 Degrees Pharmaceuticals (SXTP) Unveils Discrepancies in Babes - GuruFocus
Daily Progress: 60 Degrees Pharmaceuticals Inc (SXTP) Drop -15.51, Closing at 2.67 - DWinneX
60 Degrees Pharmaceuticals Inc (SXTP) Stock: A Comprehensive 52-Week Review - investchronicle.com
60 Degrees Pharmaceuticals Inc’s latest rating changes from various analysts - knoxdaily.com
How is SXTP’s stock performing after recent trades? - uspostnews.com
Shocking Gap: Survey Finds 3 Million Babesiosis Cases While CDC Reports Only 1,834Major Market Opportunity - Stock Titan
Babesiosis Disease Burden in United States is Substantially Higher Than Official Estimates, According to Preliminary Results of 60 Degrees Pharma Survey - Yahoo Finance
Form 8-KCurrent report - ADVFN
60 Degrees Pharma Announces $1.043 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - ADVFN
60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) Short Interest Down 43.2% in March - Defense World
Deal Watch: Oak Hill Picks Up Where Roche Left Off In Angelman Syndrome - insights.citeline.com
Why 60 Degrees Pharmaceuticals, Inc. (SXTP) Went Down On Thursday? - MSN
60 Degrees Pharma's Breakthrough: New Clinical Trials Target Rising Tick-Borne Disease Crisis - Stock Titan
Geoff Dow, PhD, Infectious Disease Product Development Expert, to Discuss Babesiosis at Healing Lyme Summit, April 15-21 - Yahoo Finance
10 Stocks Fall Behind Amid Market Optimism - Insider Monkey
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
60 Degrees Pharmaceuticals’ (SXTP) “Sell (E+)” Rating Reiterated at Weiss Ratings - Defense World
60 Degrees and Yale to progress tafenoquin for babesiosis - Yahoo
60 Degrees Pharmaceuticals (SXTP) Reports 2024 Financial Results - GuruFocus
60 Degrees Pharmaceuticals (SXTP) Announces 1-for-5 Reverse Stoc - GuruFocus
60 Degrees Pharma signs patent agreement with Yale for tick disease medicine development - Mugglehead Magazine
60 Degrees Pharmaceuticals signs Patient License Agreement with Yale - TipRanks
TNF Pharmaceuticals Inc: Navigating Market Fluctuations with a 0.75M Market Cap - investchronicle.com
60 Degrees Pharmaceuticals partners with Yale for drug development By Investing.com - Investing.com South Africa
Traders boost bets Fed will start cutting rates in May - Yahoo Finance
Mr. Yoshida's Brings the Heat with New Spicy Wing & Rib Sauce - Yahoo Finance
InventHelp Inventor Develops New Litter Removal Tool for Poultry Houses (JTK-236) - Yahoo Finance
60 Degrees Pharmaceuticals (SXTP) Stock Rallies On Tafenoquine Patent News - Stocks Telegraph
Will Assurant (AIZ) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance
Donaldson Exhibits Strong Prospects Despite Persisting Headwinds - Yahoo Finance
US trade rep says Trump tariffs are getting results, but things may be 'challenging' for awhile - Yahoo Finance
US Tariff Revenue Gains Seen as Undercut by Declining Trade - Yahoo Finance
SSL or XOM: Which Is the Better Value Stock Right Now? - Yahoo Finance
RYTM Stock Rises 17% on Meeting Goals in Hypothalamic Obesity Study - Yahoo Finance
Watch live: U.S. Trade Rep. Jamieson Greer testifying before Senate Finance Committee - Yahoo
60 Degrees Pharmaceuticals (SXTP) Teams with Yale for Tafenoquine Development - GuruFocus
Dow Jumps Over 1,100 Points; US Small Business Sentiment Falls In March - Benzinga
60 Degrees Pharmaceuticals Signs Patent License Deal to Develop Tafenoquine for Tick-Borne Disease Treatment - marketscreener.com
Sixty Degrees Pharmaceuticals Announces Patent License Agreement To Advance Development Of Tafenoquine - MarketScreener
60 Degrees Pharmaceuticals: Surge or Slump Ahead? - timothysykes.com
SXTP60 degrees pharmaceuticals, Inc. Latest Stock News & Market Updates - Stock Titan
60 Degrees Pharmaceuticals partners with Yale for drug development - Investing.com
First-Ever Babesiosis Prevention Drug: Yale Partners with Sixty Degrees on Breakthrough Treatment - Stock Titan
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Trump’s Tariff Guru Gives His Personal ‘Guarantee’ There Won’t Be a Recession - Yahoo News
These Bond ETFs Are Still Winning Amid Trump Tariff Selloff - Yahoo Finance
Indian fintech Juspay secures $60m in Series D funding - Yahoo Finance
Laurentian Bank shares an update on the progress of its strategic plan - The Globe and Mail
60 Degrees Pharmaceuticals Inc (SXTP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
60 Degrees Pharmaceuticals Inc 주식 (SXTP) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| XU CHERYL | Director |
Dec 12 '24 |
Buy |
1.82 |
5,000 |
9,125 |
46,078 |
| XU CHERYL | Director |
Dec 16 '24 |
Buy |
1.45 |
2,000 |
2,900 |
54,078 |
| DOW GEOFFREY S | President and CEO |
Dec 09 '24 |
Buy |
1.27 |
35,823 |
45,563 |
94,580 |
| DOW GEOFFREY S | President and CEO |
Dec 06 '24 |
Buy |
1.20 |
20,579 |
24,672 |
58,757 |
| DOW GEOFFREY S | President and CEO |
Dec 05 '24 |
Buy |
1.11 |
17,549 |
19,520 |
38,178 |
| DOW GEOFFREY S | President and CEO |
Nov 21 '24 |
Buy |
0.91 |
3,500 |
3,195 |
20,629 |
| DOW GEOFFREY S | President and CEO |
Nov 19 '24 |
Buy |
0.90 |
2,500 |
2,248 |
16,129 |
| DOW GEOFFREY S | President and CEO |
Nov 20 '24 |
Buy |
0.92 |
1,000 |
924 |
17,129 |
| XU CHERYL | Director |
Aug 27 '24 |
Buy |
1.70 |
5,000 |
8,500 |
41,078 |
| XU CHERYL | Director |
May 16 '24 |
Option Exercise |
0.22 |
2,000 |
446 |
228,934 |
0.52%
0.52%
자본화:
|
볼륨(24시간):